CLINICAL_TRIALS
trial_result
· 2025-02-17
Clinical Trial Update: Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis [Phase 4]
Summary
Phase 4 trial results assess the effects of ocrelizumab on B-cell tolerance defects in relapsing-remitting multiple sclerosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Johns Hopkins University | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2025-02-17